Randomized Control Trial of Small-Molecule Natural Flavonoids Intervention for Neurodegenerative Diseases
NCT05947396 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2023-08-14
Summary
1. Explore the effects of natural plant flavonoids on the positive intervention mechanism of neurotransmitter transmission physiological indicators changes (EEG) in the brain of the study subjects;
2. Investigate the effects of natural plant flavonoids in positively intervening clinical symptoms of the study subjects.
Conditions
Interventions
- DIETARY_SUPPLEMENT
-
SMARTO ONE
The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.
- OTHER
-
placebo
The placebo is provided by Beijing Jiafurui Biological Technology Co., Ltd. The formula consists of maltodextrin, grapefruit powder, and food coloring. The manufacturing facility has adjusted the appearance, color, solubility, and taste of the placebo to match the intervention agent. There is no risk of unblinding.
Sponsors & Collaborators
-
Mei Han
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 25 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-08-15
- Primary Completion
- 2024-06-15
- Completion
- 2024-12-31
More Related Trials
-
A Phase 1 Safety and Tolerability Study of TML-6 in Healthy and Elderly Volunteers for Alzheimer's Disease Treatment
NCT06562114 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])
NCT01496170 ·Status: COMPLETED ·Phase: PHASE1
-
Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease
NCT04149860 ·Status: COMPLETED ·Phase: PHASE1
-
MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)
NCT00420420 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial of a Low Protein Diet in Patients With Cognitive Impairment
NCT05480358 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)
NCT06347315 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of 1612 Capsules in aMnestic Mild Cognitive Impairment
NCT02982642 ·Status: WITHDRAWN ·Phase: PHASE4
-
Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease
NCT04576793 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment
NCT01723670 ·Status: WITHDRAWN ·Phase: PHASE2
-
Healthy Adults With Mild Cognitive Impairment (MCI) and a 16-week Intervention With Mitocholine™, a Functional Food Ingredient
NCT05690724 ·Status: RECRUITING ·Phase: NA
-
Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease
NCT03363269 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients
NCT03514875 ·Status: WITHDRAWN ·Phase: NA
-
Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease
NCT07323927 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Evaluation of the Effects of a Food Supplementation on the Improvement of Cognitive Functions in Healthy Seniors
NCT05472285 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
NCT05602727 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
NCT01689233 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of MEMORMAX in Subjects With MCI
NCT03581929 ·Status: COMPLETED ·Phase: NA
-
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
NCT01374438 ·Status: COMPLETED ·Phase: PHASE2
-
Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia
NCT05227820 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
NCT00105547 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
NCT02957682 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease
NCT04346862 ·Status: UNKNOWN ·Phase: PHASE4
-
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
NCT01429623 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of a Plant Based Nootropic on Perceptual Decision Making.
NCT06689644 ·Status: COMPLETED ·Phase: NA
-
Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
NCT05363293 ·Status: COMPLETED ·Phase: PHASE1/PHASE2